Biomedical subjects

R García-Delgado

Publications and source records attributed to R García-Delgado.

4 recordsLinked to original sources

PubMed1997

[Monitoring of gentamycin serum concentration in neonates. Usefulness in adjustment of dosage].

OBJECTIVE: The objective of this study was to confirm the variation of the pharmacokinetic parameters of gentamicin in neonates and to establish guidelines for a dosage regimen. PATIENTS AND METHODS: A study was made of 89 neonates being treated with gentamicin. The gestational ages ranged from 25 to 41 weeks and the postnatal age between 1 and 30 days. Weights were between 600 and 4,400 grams. The average dose was 2.45 +/- 0.4 mg/kg/dose. Groups were established according to gestational age (under 34 weeks, 34-37 weeks and over 37 weeks) and postnatal age (over and under 7 days old). RESULTS: The elimination half-life (t1/2) was significantly reduced (p < 0.01) in the different age groups. The distribution volume (V) showed a slight decrease corresponding to the gestational age, but this was not significant. The results suggest that the dosages applied in mg/kg were sufficient to attain potentially therapeutic peak blood levels (Cmax). However, the dosage should be administered at different intervals according to the age groups in order to allow the trough levels (Cmin) to come down to values which are considered to be therapeutic. CONCLUSIONS: An interval of 24 hours is recommended for preterm babies with a postnatal age of less than 7 days and an interval of 12 hours for the remainder of the infant population.

Anti-Bacterial Agents↗

PubMed1994

B-cell follicular lymphomas: clinical and biological characteristics.

Seventy cases of follicular B-cell lymphomas were studied: 37 cases derived from the follicular centre [27 centroblastic-centrocytic (CB-CC) and 10 centroblastic (CB)] and 33 from the mantle zone [mantle-cell lymphoma (ML)]. Presenting features as well as response to therapy, time free of symptoms and survival were reviewed. All the cases were diagnosed and classified with routine and immunohistochemistry methods. In 61 cases tumors were studied with specific markers in a CAS-200 Image Analyser. Flow cytometry (FCM) was also done and correlated with proliferative-values and survival. A minor aggressive course of CB-CC and ML was demonstrated, with ML being the most benign form (lower proliferation rate and longest survival). Ploidy did not correlate with histological subtypes, survival or response to therapy. These results confirm the utility of biodynamic studies in lymphoid neoplasias.

Adult↗

PubMedDate not supplied

[Possible gabapentin phenytoin interaction].

INTRODUCTION: We report a possible case of gabapentin induced phenytoin toxicity. CASE REPORT: White man, 26 years old, chronically treated with phenytoin (for the past 4 years) and gabapentin (for the past 17 months). He was seen after complaining of dysarthria, ataxia and vertigo for the past 3 months, although having noted slight dizziness and a general, though undefined, indisposition from the start of taking gabapentin. The total and free serum levels of phenytoin found were clearly toxic. Gabapentin was discontinued definitively, and phenytoin for the next 7 days. The clinical symptoms had disappeared completely and phenytoin returned to within therapeutic levels. According to the criteria of causation it can be considered a possible adverse reaction caused by phenytoin related to incorporation of gabapentin. The mechanisms of this possible drug interaction are discussed, with emphasis on cytochrome P450 metabolism. CONCLUSION: The present case is a warning of the possible interaction of a drug (gabapentin) not contemplated when starting or when monitoring an antiepileptic treatment.

Acetates↗

PubMedDate not supplied

[Can treatment associated with ticlopidine and nifedipine increase serum levels of phenobarbital?].

INTRODUCTION: We report a case in which the association between ticlopidine, nifedipine and phenobarbital was linked with a higher than expected phenobarbital concentration in serum, which suggested a possible interaction between these drugs. CASE REPORT: A 67 year old male who received treatment with phenobarbital, digoxin, nifedipine, ticlopidine, paroxetine and clorazepate dipotassium. The first control of the level of phenobarbital in serum was performed without any symptoms or signs of toxicity or ineffectiveness. A phenobarbital concentration in serum of 21.4 mg/L was obtained, with a serum level/dosage ratio of 16.7. DISCUSSION: The serum level/dosage ratio of phenobarbital that was found in this case is almost twice as high as expected. In the absence of other factors that can explain this finding, we believe that two drugs (ticlopidine and nifedipine) may be involved in an interaction with phenobarbital. CONCLUSIONS: The high value of the serum level/dosage ratio that was found makes it advisable to monitor the concentrations of phenobarbital in serum in treatment associated with ticlopidine or nifedipine, especially when adjusting the dosage, beginning or ending treatment with these drugs.

Aged↗